Long-Acting Beta-Agonists Show No Clear Benefits in Children With Asthma
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Long-Acting Beta-Agonists Show No Clear Benefits in Children With Asthma

CHICHESTER, United Kingdom -- December 10, 2008 -- There are no clear benefits to using long-acting beta2-agonists (LABAs) for treatment of asthma in children, according to an overview of recent Cochrane reviews published in the December issue of Evidence-Based Child Health.

Child Health field researchers reported that there is currently insufficient evidence to suggest that the drugs offer any additional benefit over regular inhaled corticosteroids (ICS) therapy.

"We found no evidence to suggest that LABA should be used alone or in combination with ICS in the majority of young asthma sufferers. ICS should remain the therapy of choice," said lead author Amy Plint, MD, University of Ottawa, Ottawa, Ontario.

The overview included 4 previous reviews of trials in children aged over 4 years. Together, the trials showed that ICS in combination with LABAs significantly improved lung function compared with ICS combined with placebos.

LABAs did not, however, reduce severity of asthma symptoms as measured by hospital admissions or the need for steroid medication.

The researchers said more long-term trials are needed to establish the effectiveness of LABAs in children. However, they think that the drugs may improve lung function in the most severe cases.

"We should not rule out combination therapy as a treatment option in children with poorly controlled asthma despite compliance with moderate dose ICS agents," said Dr. Plint.

SOURCE: Wiley-Blackwell

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities